Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2013
Mammographic breast density response to aromatase inhibitionCeline M Vachon, Vera J Suman, Kathleen R Brandt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trialVered Stearns, Judith-Anne W Chapman, Cynthia X Ma, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research and Treatment|February 19, 2018
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)Lynne I Wagner, Fengmin Zhao, Paul E Goss, et al.
Clinical Breast Cancer|November 13, 2017
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27Polly Niravath, Bingshu Chen, Judy-Anne W Chapman, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
Molecular Endocrinology (Baltimore, Md.)|August 23, 2014
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomicsMohan Liu, Paul E Goss, James N Ingle, et al.
The Oncologist|December 1, 2018
Patient Navigation to Enhance Access to Care for Underserved Patients with a Suspicion or Diagnosis of CancerYanin Chavarri-Guerra, Enrique Soto-Perez-de-Celis, Wendy Ramos-López, et al.
Pageof 25